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In order to study receptor abundance and its function in solutions or in homogenates from clinical specimen, methods such
as sandwich or radioimmunoassays are most commonly employed. For the determination of epidermal growth factor receptor
(EGFR), we describe the development of a miniaturized bead-based ligand binding assay using its ligand EGF as immobilized
capture reagent. This assay was used to analyze lysates from cell lines, and the ligand-bound EGFR was detected using an EGFR-
speciﬁc antibody combined with a ﬂuorescence-based reporter system. In a proof-of concept study with lysates from breast
biopsies, the assay allowed to classify breast cancer samples in accordance to clinically the relevant EGFR cut-oﬀ level. The
study suggests that such a ligand binding receptor assay could become an integral part of protein proﬁling procedures to provide
additional information about receptor functionality in addition to its abundance.
1.Introduction
Since their introduction in the 1960s [1], immunoassays
based on radiolabeled ligands or antibodies have become
well-established technologies in research and clinical chem-
istry. Today, antibody-based immunoassays have been trans-
ferred and applied to various technological platforms such
as multiplexed and miniaturized formats used in proteomic
experiments [2, 3]. These multiplexed assay systems now
allow analyzing hundreds of proteins in a single aﬃnity-
based experiment, but, thus far, radioimmunoassay-like
measurementsofligandbinding activereceptorshavenot yet
been transferred in a miniaturized format.
In the context of a detailed analysis of breast cancer,
the quantiﬁcation of active epithelial growth factor receptor
(EGFR) in clinical specimen is a prominent example for the
application of a radio-ligand binding assay. The investigation
of receptor tyrosine kinases such as the EGFR is of interest,
as overexpression of EGFR is correlated with poor prognosis
[4],andtheexpressionratesofEGFRandhormonereceptors
were strongly inverse [5]. EGFR itself is a transmembrane-
spanning protein, with an extracellular ligand binding and
a cytoplasmatic tyrosine kinase domain [6], and its main
ligand EGF is a polypeptide consisting of 53 amino acids
that binds to domain I and III of the extracellular part of
the receptor. Upon binding of EGF to EGFR, the receptor
undergoes conformational changes [7]. These lead to a
downstream activation of the NF-κB transcription factor
pathway to induce antiapoptotic and proliferated genes,
which eventually results in cell growth. EGFR plays a key
role in the regulation of essential normal cellular processes
and in the pathophysiology of hyperproliferated diseases
such as many epithelial cancer types like breast, ovarian,
lung, colorectal or prostate cancer [8]. EGFR is also known
to be activated in a variety of tumors via the promotion
of its gene c-erbB1, leading to an overexpression [9]b y
mutation or ligand binding [10]. EGFR expression may
even serve as a decision maker for EGFR-targeted therapies
[11], and, recently, the use of speciﬁc monoclonal antibodies
directed against the phosphorylated and mutant form of2 International Journal of Proteomics
EGFR (EGFRvIII) was suggested as a valid predictor of
response to therapy with cetuximab, an anti-EGFR antibody
[12].
To measure the levels of EGFR in tissue samples,
sandwich immunoassays can be used [13]. Complementary
to these, radio-ligand binding assays (RLB) perform a more
classical approach to measure quantities of functional EGFR
by employing 125I-labeled EGF [14]. This receptor ligand
binding assay takes advantage of the strong interaction
between the ligand EGF and EGFR, which bind with an
aﬃnity of ≤12nM [15].
In the study presented here, we have developed a minia-
turized solid-phase-based ligand binding assay as a possible
alternative to assays involving radioactive tracers. Instead
of using an EGFR speciﬁc antibody, we have employed the
ligand EGF as a reagent to capture and proﬁle functional
EGFR present in the samples. This assay only requires small
amountsofsampletodeterminerelativeEGFRlevelinlysates
from cell culture material as well as from patient samples.
The study reveals that bead-based ligand binding assay oﬀers
a complementary system to sandwich immunoassays and
radioimmunoassays.
2.Methods and Material
2.1. Preparation of Cell Samples. Frozen pellets of the
human breast cancer cells BT-20 (ATCC no. HTB-19) were
solubilized on ice with 2% (v/v) NP-40 (Sigma) in a buﬀer
containing 50mM Tris (Sigma), 120mM NaCl, 1mM CaCl2,
1mMMgCl 2, and 2% (v/v) protease inhibitor (Sigma). The
cells were sonicated 4 times for 5s (Branson Soniﬁer, Korea)
and centrifuged at 13,000rpm for 5min. The supernatant
was collected for further studies.
2.2. Tissue Samples. Membrane fractions of 46 breast cancer
samples with EGFR levels between 0 and 600fmol EGFR per
mg protein were included in the study (Supplementary Table
1 available online at doi:10.1155/2012/247059). The EGFR
level was analyzed by a radio-ligand binding assay [14].
Seventeen samples had an EGFR level ≤10fmol/mg, and 29
samples had EGFR levels of 11–246fmol/mg. One sample
h a da nE G F Rc o n c e n t ra t i o no f6 0 0f m o l / m g.A l ls a m p l e sh a d
been stored at −80◦Cf o ra b o u t1 0y e a r s .
2.3. Coupling of Beads. Biotinylated EGF (EGF-Biot, Molec-
ularProbes)wascoupledtoavidin-coatedbeads(LumAvidin
beads, Luminex Corporation). In each coupling reaction, 2.5
× 105 beads were used. Firstly, beads were washed twice in
block-and-storagebuﬀer(BSB)containing1%bovineserum
albumin (Carl Roth) in phosphate-buﬀered saline (pH
7.4). Washing steps were performed as follows: beads were
sedimented at 10,000g for 2min, supernatant was removed,
and beads were resuspended with 250μLB S B ,v o r t e x e d ,
and sonicated. EGF was coupled onto two diﬀerently color-
c o d e db e a ds e t sa tE G F - B i o tc o n c e n t r a t i o n so f1 . 2μMa n d
0.3μM over 30min under permanent shaking in BSB buﬀer.
Beads were washed twice with BSB and stored in BSB buﬀer
containing 0.01% sodium azide (Merck) at 4◦C in the dark
before use.
2.4. Miniaturized Ligand Binding Assay. Assays were per-
formed in a 96-well microtiter plate with a ﬁlter-membrane
bottom (Millipore) in BSB under permanent shaking at
650rpm and 23◦C in the dark. In each well, 30μL containing
EGF-Biot beads (1000 per set) and 30μLo fs a m p l ew e r e
mixed and incubated for 2h. The beads were washed with
3 × 50μLB S Bb u ﬀer on a vacuum manifold (Millipore).
An anti-EGFR antibody (0.3μg/mL, mAb11, LabVision) was
selected, and 30μL were added to each well. After an incu-
bation of more than 60min, the beads were washed again
as above. A secondary R-phycoerythrin-labeled antibody
(2.0μg/mL, goat anti-mouse, Dianova) with a volume of
30μL/well was incubated for 45min. Finally, the beads were
washed, and a ﬁnal volume of 75μL BSB was added to each
well.
For competition experiments, soluble EGF (sEGF,
Biomol) was mixed with the sample and coincubated with
immobilized EGF-Biot-coupled beads. For detection, anti-
EGFR antibody mAb11 was applied at 1.25μg/mL and the
labeled anti-mouse antibody at 5.0μg/mL.
2.5. Readout and Data Analysis. A Luminex LX100 system
(Luminex Corporation) was used to determine the bead-
bound reporter ﬂuorescence. For each well, at least 100
events per bead ID were counted and the median ﬂuores-
cence intensity (MFI) of the reporter dye was collected. Data
was processed using R, a language and environment for
statistical computing and graphics [16]. For the comparison
of two groups with diﬀering EGFR expression values, a P
value was calculated with Student’s t-test.
3. Results
In a ﬁrst set of experiments, two concentrations of biotiny-
lated EGF were immobilized onto beads, mixed, and applied
to an assay with diﬀerent amounts of total protein from cell
lysates. For this study, BT-20 cells, known to express EGFR at
level of 400fmol/mg or 1.5 × 106 copies per cell [17], were
chosen. For the subsequent detection of bead-bound EGFR,
an anti-EGFR antibody was chosen that did not interfere
with the EGF-EGFR interaction, according to the data sheet.
No cross-reactivity between immobilized EGF-biotin, the
anti-EGFR antibody, and the labeled anti-mouse detection
antibody could be detected (data not shown). In Figure 1(a),
it is shown that both the amount of lysate employed as
well as the ligand density on the bead surface inﬂuenced
the measured signal intensity and no saturation eﬀects were
observed for the tested lysate protein concentrations. EGF
coupled to the beads at a concentration of 1.2μM showed
increased signal intensities compared to the bead ID coupled
with a 4x lower ligand concentration, in addition to a
broader intensity range for the 1.2μMl o a d e dE G Fb e a d s .
As the utilized BT-20 cells are known to express higher
levelsofEGFR,asampleproteinconcentrationof500μg/mL,
reﬂecting 15μg of total protein per well, was chosen forInternational Journal of Proteomics 3
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Figure 1: (a) Detection of EGFR in cell extracts. Beads coated with diﬀerent concentrations of EGF were used to capture EGFR from a cell
lysate in a concentration-dependent manner. The ligand EGF was immobilized at 1.2μM (diamonds) and 0.3μM( c i r c l e s )o nd i ﬀerent bead
types. Both bead sets were mixed and incubated with diﬀerent amounts of BT-20 cell lysates. Captured EGFR was detected using an anti-
EGFR antibody and a labeled secondary antibody. (b) Speciﬁcity of capture activity. A BT-20 cell lysate (500μg/mL) was coincubated with
variousconcentrationsofpuriﬁedandunbiotinylatedsEGFandbeadscoatedwithEGF-Biot(1.2μM).TheamountofcapturedEGFreceptor
was strongly reduced at the presence of sEGF. This indicates that the bead-bound EGF-EGFR complex is captured in a speciﬁc fashion by
applying an anti-EGFR antibody followed by a labeled secondary antibody. (c) Correlation of ligand binding and sandwich immunoassay.
A series of tissue lysates with known EGFR concentrations were analyzed with both, a ligand binding assay and an immunoassay using an
antibody as capture reagent. In both assays, the same anti-EGFR detection molecule was used and the proﬁles obtained reveal a correlation
of 0.94, which indicated a good concordance between the two tests.
the following studies to also facilitate the detection of EGFR
in specimens with lower expression levels. To validate the
speciﬁcity of the assay, meaning that EGF is capturing EGFR,
BT-20 cell lysates were coincubated with nonbiotinylated
soluble EGF (sEGF). In this competition assay, sEGF will
bind to free EGFR binding sites and occupy them so that
the immobilized EGF cannot bind to such a EGFR molecule.
The results from this test (Figure 1(b)) showed a strong
reduction in signal intensity at sEGF levels of 11.5nM (96%
reduction) and 2nM (89% reduction). This clearly indicated
thattheobservedinteractionsareduetoEGFR-EGFbinding.
Moreover, we also compared the ligand binding assay to a
sandwich immunoassay with both tests being performed on
beads and utilizing the same detection system. As shown
in Figure 1(c), a concordance of r = 0.94 was achieved
for the proﬁles generated with breast cancer tissue samples4 International Journal of Proteomics
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Figure 2: Analysis of breast cancer tissue samples. Forty-six breast
cancer tissue samples originally analyzed for EGFR expression by a
radio-ligand binding assay were reanalyzed in a bead-based ligand
binding assay. A cut-oﬀ value of 10fmol EGFR per mg protein,
determined by radio-ligand binding assay, was used to divide the
samples into group A (n = 17) with EGFR values ≤10fmol/mg and
group B (n = 29) with EGFR values >10 fmol/mg. Samples were
measuredinarandomorder,andaP valueof2.6e-11wascalculated
between the two groups.
(see below). This demonstrated that a protocol for a ligand
binding assay was developed and that is allowed to provide
speciﬁc and functional information for proﬁling the cell
surface receptor EGFR in lysates.
Next, the EGFR ligand binding assay was applied in a
proof-of-concept study to proﬁle EGFR in 46 tumor samples
derived from breast cancer patients. The tissue lysates were
measured in random order at a total protein concentration
of 0.5mg/mL with the established protocol. The analyzed
samples were grouped based on a clinically relevant cut-
oﬀ level of 10fmol/mg [5], which had been previously
determined in radio-ligand binding experiments. As shown
in Figure 2,1 5o f1 7s a m p l e s( 8 8 % )f r o mg r o u pAw i t h
EGFR ≤10fmol/mgweremeasuredwithMFIs ≤25AU,while
samples with MFI ≥50AU were not aﬃliated to this group.
For samples in group B with EGFR >10fmol/mg, 52% had
MFI values ≥50AU, and, for the remaining 48% with MFIs
≤50AU, the highest EGFR value was 42fmol/mg. A sample
containing 600fmol/mg EGFR (not shown in Figure 2)w a s
measured with an MFI >1000AU thus served as a control.
Between group A and B, a P v a l u eo f2 . 6 e - 1 1w a sc a l c u l a t e d
and demonstrated that the ligand binding assay performed
well to provide complementary evidence for separating
samples with high and low EGFR values.
4. Discussion and Conclusion
Miniaturized ligand binding assays, as described here for
EGF and EGFR, oﬀer a radiation-free tool to proﬁle and
study target molecules via their in vivo interaction partners
compared to conventional radioimmunoassays or other
antibody-based methods. In the presented approach, we
investigate the potential of the immobilized receptor ligand
EGF to capture EGFR in a miniaturized bead-based assay
format in which EGF was immobilized to avidin-coated
beads via an N-terminal biotin modiﬁcation. The chosen
immobilization strategy enabled to maintain the binding
propertiesofEGFandtoachievehighsignalintensities.Both,
the EGF coupling concentration as well as the amount of
the applied sample aﬀected signal intensities. As described
elsewhere, the extracellular domain of EGFR undergoes a
conformational change upon ligand binding on the cell
surface [7] and it seemed likely that such changes should
occur even when EGFR is being bound by an immobilized
capture ligand. Even though EGF-EGFR interactions take
place with a free EGF binding to anchored or soluble EGFR
in vivo, attaching EGF to a solid support did not hinder the
two proteins from binding to each other.
In competition assays, it was revealed that the binding
by detected immobilized EGF was aﬀected by puriﬁed and
solublesEGF,thusconﬁrmingthatthemeasuredinteractions
were from EGF and EGFR. The strong inhibitory eﬀect of
soluble EGF is likely to reﬂect advantages in conformation
adaptation of EGFR when binding in solution. Compared
with purely antibody-based sandwich immunoassays, that
were described earlier [18], the inﬂuence of conformational
may have a greater inﬂuence on the ligand binding assay.
This could be interpreted from the decreased intensity level
that was found in ligand binding assays. In addition, this
observation may eventually be a consequence of the fact that
the total number of receptors accessible to ligand binding is
lower due to the applied extraction procedure and sample
storage, which may not keep all receptors in nondenatured
and functional states.
To investigate the possible potential applicability of
this approach in future clinical sample analysis, EGFR-
characterized tumor samples from breast cancer patients
were studied. The analyzed samples were grouped based
on a clinically relevant cut-oﬀ level for EGFR, and it was
possibletodiscriminatesampleswithexpressionlevelsbelow
or above cutoﬀ using the described assay setup. Even though
this small proof-of-concept study may suggest that such
miniaturized ligand binding approaches could have the
potential to be a supplementary alternative to radioactivity-
based tests, further testing and assay evaluations need to be
performed.
The demonstrated miniaturization of receptor ligand
binding assays allowed an analysis of potentially functional
receptorsfromminimalsampleamountsandwoulddecrease
costs by reducing the amount of material and reagents
needed. The reduction of sample volume would be of
particular importance for applications where only minimal
amounts of specimen are available, such as the analysis
of multiple tumor markers from biopsies. In addition, the
miniaturized ligand binding assays may have the capability
to supplement existing single- or multiplexed sandwich
immunoassays to further increase the evidence for speciﬁc
target presence and to add informatory value.International Journal of Proteomics 5
In conclusion, the ligand binding assay system demon-
strates that ligand receptor-binding assays can be minia-
turized and oﬀer to become part of the variety of protein
microarray-based approaches performed today. With new
proteins and pathways emerging as indicators of disease, the
procedure presented here describes a possibility to proﬁle
the interactions of proteins, such as cell surface receptors,
in a miniaturized assay. It is possible that such assays are
of value for variety of assays in the ﬁelds of proteomics and
diagnostics.
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